Table 2. Univariable Cox proportional hazards models of uric acid and clinic-pathological parameters for the prediction overall and PFS in patients with DLBCL (n=539).
|
Univariable analysis of OS |
Univariable analysis of PFS |
|||
|---|---|---|---|---|
| Variable | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Uric acid (per 1 log increase) | 1.60 (1.16–2.19) | 0.004 | 1.47 (1.10–1.97) | 0.009 |
| Uric acid (per 1 mg dl−1 increase) | 1.02 (1.00–1.05) | 0.031 | 1.02 (1.00–1.04) | 0.102 |
| Uric acid | ||||
| <75th percentile | 1 (ref.) | – | 1 (ref.) | – |
| ⩾75th percentile | 1.65 (1.20–2.29) | 0.002 | 1.53 (1.14–2.06) | 0.005 |
| Uric acid | ||||
| <ROC cut-off | 1 (ref.) | – | 1 (ref.) | – |
| ⩾ROC cut-off | 3.74 (2.44–5.73) | <0.0001 | 3.11 (2.05–4.70) | <0.0001 |
| BMI (per 5 kg m−2 increase) | 0.93 (0.68–1.27) | 0.647 | 0.91 (0.70–1.19) | 0.503 |
| Age at diagnosis (per 5 years increase) | 1.30 (1.21–1.39) | <0.0001 | 1.17 (1.11–1.24) | <0.0001 |
| LDH (per 100 units increase) | 1.04 (1.03–1.06) | <0.0001 | 1.04 (1.03–1.06) | <0.0001 |
| Serum creatinine (per 1 mg dl−1 increase) | 1.16 (1.02–1.31) | 0.024 | 1.10 (0.96–1.26) | 0.153 |
| Location | ||||
| Graz | 1 (ref.) | – | 1 (ref.) | – |
| Salzburg | 1.09 (0.80–1.48) | 0.586 | 0.83 (0.63–1.10) | 0.193 |
| Gender | ||||
| Female | 1 (ref.) | – | 1 (ref.) | – |
| Male | 0.86 (0.63–1.16) | 0.315 | 0.83 (0.63–1.10) | 0.193 |
| Age category | ||||
| ⩽40 years | 1 (ref.) | – | 1 (ref.) | – |
| 41–60 years | 1.91 (0.55–6.67) | 0.307 | 1.40 (0.63–3.10) | 0.408 |
| 61–75 years | 4.76 (1.49–15.15) | 0.008 | 2.40 (1.16–4.96) | 0.018 |
| >75 years | 10.86 (3.43–34.36) | <0.0001 | 4.22 (2.05–8.71) | <0.0001 |
| Site | ||||
| No extranodal disease | 1 (ref.) | – | 1 (ref.) | – |
| Extranodal disease | 1.26 (0.93–1.70) | 0.140 | 1.22 (0.93–1.60) | 0.159 |
| LDH ratio | ||||
| <ULN | 1 (ref.) | – | 1 (ref.) | – |
| 1–3 × ULN | 1.60 (1.13–2.26) | 0.008 | 1.52 (1.12–2.07) | 0.007 |
| >3 × ULN | 3.05 (1.92–4.84) | <0.0001 | 2.72 (1.77–4.17) | <0.0001 |
| Clinical stage (Ann Arbor) | ||||
| I&II | 1 (ref.) | – | 1 (ref.) | – |
| III&IV | 1.83 (1.34–2.49) | <0.0001 | 1.67 (1.27–2.20) | <0.0001 |
| ECOG PS | ||||
| 0–2 | 1 (ref.) | – | 1 (ref.) | – |
| ⩾2 | 2.75 (1.96–3.85) | <0.0001 | 2.20 (1.60–3.02) | <0.0001 |
|
Prognostic indices | ||||
| R-IPI | ||||
| Very good | 1 (ref.) | – | 1 (ref.) | – |
| Good | 7.07 (1.74–28.78) | 0.006 | 3.54 (1.44–8.69) | 0.006 |
| Poor | 14.54 (3.58–59.07) | <0.0001 | 6.54 (2.66–16.06) | <0.0001 |
| NCCN-IPI | ||||
| Low | 1 (ref.) | – | 1 (ref.) | – |
| Low intermediate | 3.65 (0.88–15.17) | 0.075 | 1.57 (0.71–3.45) | 0.263 |
| High intermediate | 9.38 (2.30–38.19) | 0.002 | 3.00 (1.39–6.47) | 0.005 |
| High | 21.32 (5.19–87.64) | <0.0001 | 6.34 (2.88–13.93) | <0.0001 |
Abbreviations: BMI=body mass index; CI=confidence interval; DLBCL=diffuse large B-cell lymphoma; ECOG PS=Eastern Cooperative Oncology Group (ECOG) performance status (PS); HR=hazard ratio; LDH=lactate dehydrogenase; mg/dl=milligram per decilitre; NCCN-IPI=National Comprehensive Cancer Network International Prognostic Index; OS=overall survival; PFS=progression-free survival; P=Wald-test P-value; ref=reference category; R-IPI=revised international prognostic index; ULN=upper limit of normal. Bold indicates P<0.05.